Revenue and Profitability - The company's revenue for the interim period of fiscal year 2026 was approximately HKD 342.4 million, an increase of about HKD 26.6 million or 8.4% compared to the same period in fiscal year 2025[9]. - Revenue from primary care services increased by approximately HKD 7.3 million or 3.5% to about HKD 213.9 million, driven by an increase in patient visits[10]. - Revenue from dental services surged by approximately HKD 18.9 million or 67.5% to about HKD 46.8 million, primarily due to increased patient visits and the acquisition of Youde Dental Clinic[10]. - The group's profit for the interim period of FY2026 increased by approximately HKD 2.1 million or 12.3% to about HKD 18.9 million compared to FY2025[22]. - The net profit attributable to the company's owners for the interim period of FY2026 was approximately HKD 18.3 million, an increase of about HKD 1.5 million or 8.5% from FY2025[23]. - The group maintained a net profit margin of approximately 5.5% in FY2026 interim period[22]. - The group reported a net profit of HKD 18,898,000 for the period, compared to HKD 16,822,000 in the previous year, representing an increase of 12.3%[115]. Costs and Expenses - The cost of services provided rose by approximately HKD 15.8 million or 9.5% to about HKD 182.9 million, mainly due to increases in doctor and dentist fees and medical supplies costs[11]. - Administrative expenses rose by approximately HKD 6.3 million or 4.9% to about HKD 135.2 million, primarily due to increased employee-related expenses[18]. - Total costs of services provided amounted to HKD 182,881,000, an increase from HKD 167,070,000, primarily driven by higher costs for medical supplies and doctor fees[119]. Operational Developments - The group is actively participating in public health programs, enhancing community health services through collaborations with the Hong Kong government[27]. - The group is focusing on expanding telemedicine services and preventive health initiatives, including weight management programs and metabolic health screenings[26]. - The group is enhancing its integrated healthcare platform, H2, by expanding preventive medical services and personalized treatment plans[31]. - The group aims to strengthen its operational coordination and digital integration in the dental segment to establish long-term synergies[29]. - The group enhanced its diagnostic services by strengthening health education and customer interaction, including daily health consultations and a series of educational seminars on lifestyle management and disease prevention[32]. - The H2 community pharmacy offers various services, including pharmacist consultations, customized medication, and health screening services, aiming to optimize patient choices and experiences[32]. Workforce and Employment - As of December 31, 2025, the group had 408 full-time employees and 272 part-time employees, an increase from 388 full-time and 377 part-time employees as of December 31, 2024[69]. - The company has a diverse and skilled healthcare team of 464 members, including general practitioners, specialists, and various healthcare professionals, ensuring comprehensive and patient-centered care[46]. Financial Position - The net current assets as of December 31, 2025, were approximately HKD 414.7 million, an increase from HKD 383.9 million as of June 30, 2025[56]. - The company’s interest-bearing bank borrowings were approximately HKD 16.1 million as of December 31, 2025, with a capital debt ratio of about 2.0%[57]. - The company has approximately HKD 100.0 million in undrawn loan facilities as of December 31, 2025, maintaining financial flexibility[57]. - The company’s total assets as of December 31, 2025, were HKD 1,468,963,000, a decrease from HKD 1,471,571,000 as of June 30, 2025[98]. - The company’s cash and cash equivalents increased to HKD 474,531,000 from HKD 439,903,000, showing a growth of 7.8%[97]. Investments and Acquisitions - The company will continue to optimize synergies following the acquisition of Youde Dental, focusing on expanding high-end dental restoration and cosmetic services[50]. - The investment in the limited partnership is recorded at fair value, with a fair value of approximately HKD 61.0 million as of December 31, 2025, representing about 5.8% of the total assets of the group[64]. - The group recorded a fair value loss of approximately HKD 2.2 million related to the investment in the limited partnership[64]. Shareholder Information - The company’s issued share capital remains at HKD 3,796,000, with 379,552,233 shares issued as of both December 31, 2025, and June 30, 2025[141]. - As of December 31, 2025, the company’s major shareholders, including Mr. Chan and Dr. Pang, hold approximately 66.49% of the issued shares through a controlled corporation[84]. Stock Options and Incentives - The company has adopted a stock option plan, with 3,200,000 options granted and 150,000 options unexercised as of December 31, 2025[77]. - The exercise price for the stock options is set at HKD 2.09, with the options exercisable from June 1, 2021, to May 31, 2027[82]. - The total number of stock options and share rewards authorized for grant under the plans is capped at 37,955,223 shares, representing approximately 10% of the issued shares as of the adoption date[81]. Market Outlook - The company maintains a cautiously optimistic outlook for the Hong Kong private healthcare sector, driven by strong demand from an aging population and increasing health awareness[49].
盈健医疗(01419) - 2026 - 中期财报